A Phase 2 interventional study of Mometasone furoate/formoterol fumarate (MFF) and Formoterol fumarate 12 μg pMDI (F12M) in Asthma, sponsored by Novartis. Completed at 9 sites in 3 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2011-06-07.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing Mometasone Furoate in Asthma — none open to participants now, none under way, none of them phase 3. Mometasone Furoate · Asthma.
Among the 31 studies testing Mometasone Furoate in Asthma, this one is the 23rd largest by enrollment, is one of 3 that started in 2008, is one of 6 in phase 2, and was the 16th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →None of the 31 studies testing Mometasone Furoate in Asthma is open now. The open studies under Asthma, anywhere →
Mometasone Furoate: first FDA approval 1987 (ELOCON), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 92 across the 31 interventional studies. Of the 28 that completed or were terminated, 25 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 31 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
105 studies in Asthma by Novartis: 3 open now, 5 under way, 2 of them phase 3. Of 93 finished, 61 (66%) have results posted.
Among the 105 studies in Asthma by Novartis, this one is the 80th largest by enrollment of the 97 interventional ones that give a count, is one of 9 that started in 2008, is one of 43 in phase 2, and was the 30th registered.
Novartis’s Asthma studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 31 studies testing Mometasone Furoate in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 105 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to compare the pharmacodynamics (bronchodilation, onset and duration of action), of a single dose of formoterol fumarate in combination with mometasone furoate to placebo in children of 5-11 years with persistent asthma. The study will also assess the bronchodilatory effect of a single dose of formoterol fumarate alone and in combination with mometasone furoate delivered via a pressurized metered dose inhaler (pMDI) to the bronchodilatory effect of formoterol fumarate delivered via a dry powder inhaler (DPI). Furthermore, pharmacokinetic assessments of plasma and urine will also be conducted throughout the study to assess systemic exposure following administration of the study medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
Drug: Mometasone furoate/formoterol fumarate (MFF) · Drug: Formoterol fumarate 12 μg pMDI (F12M) · Drug: Formoterol fumarate 12 μg DPI (F12D) · Drug: Placebo to F12D · Drug: Placebo to F12M/MFF
Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
Drug: Mometasone furoate/formoterol fumarate (MFF) · Drug: Formoterol fumarate 12 μg pMDI (F12M) · Drug: Formoterol fumarate 12 μg DPI (F12D) · Drug: Placebo to F12D · Drug: Placebo to F12M/MFF
Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
Drug: Mometasone furoate/formoterol fumarate (MFF) · Drug: Formoterol fumarate 12 μg pMDI (F12M) · Drug: Formoterol fumarate 12 μg DPI (F12D) · Drug: Placebo to F12D · Drug: Placebo to F12M/MFF
Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
Drug: Mometasone furoate/formoterol fumarate (MFF) · Drug: Formoterol fumarate 12 μg pMDI (F12M) · Drug: Formoterol fumarate 12 μg DPI (F12D) · Drug: Placebo to F12D · Drug: Placebo to F12M/MFF
Drug pages: Mometasone Furoate · Formoterol
Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
Placebo to formoterol fumarate DPI delivered via DPI
Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment
For FEV1 AUC(0-12h) the trapezoidal rule was applied using planned time measurements to calculate the AUC up to and including the last measurement recorded before intake of rescue medication. The AUC was standardized by dividing by the length of time for which measurements of FEV1 were included in the calculation of the AUC thus adjusting for subjects who were unable to complete the measurements during the 12-hour observation period and without inhaling rescue medication. The unit of the AUC was in L, being a weighted average of the acceptable FEV1 measurements recorded over 12 hours post dose
Time frame: From 0 to 12 Hours (0-12h) post-dose, after each treatment administered (approximately 1 treatment a week for 4 weeks of treatment).
Serial FEV1 Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect
All efficacy evaluations were based on spirometry assessments of lung function. FEV1 is the maximum amount of air expired in one second. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the (ATS / ERS) standards.
Time frame: 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose
Serial Forced Vital Capacity (FVC) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect
All efficacy evaluations were based on spirometry assessments of lung function. FVC is the volume (liters) of air that can forcibly be blown out after full inspiration. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS / ERS standards.
Time frame: 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose
Serial Peak Expiratory Flow Rate (PEF) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect
All efficacy evaluations were based on spirometry assessments of lung function. PEF is the greatest airflow rate achieved during forced exhalation with lungs fully inflated. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS/ERS standards
Time frame: 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose
Plasma Formoterol Concentrations (Pmol/L) Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)
Unchanged racemic formoterol in plasma was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for plasma was 1.45 pmol/L. No non-compartmental PK analysis was performed.
Time frame: 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose
Urinary Excretion of Formoterol Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)
Unchanged racemic formoterol in urine was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for urine was 0.0174 nmol/L expressed as free base. The amounts of unchanged formoterol excreted in urine from 0 to 3 hours (Ae0-3) and from 0 to 12 hours post-dose (Ae0-12) were calculated from the formoterol concentrations in urine and the urine volumes using non-compartmental methods.
Time frame: 0 to 3 hrs and 0-12 hrs
| Milestone | F12M, PL, F12D, MFF | F12D, F12M, MFF, PL | MFF, F12D, PL, F12M | PL, MFF, F12M, F12D |
|---|---|---|---|---|
| Started | 7 | 9 | 9 | 7 |
| Completed | 7 | 9 | 8 | 7 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Abnormal test procedure result | 0 | 0 | 1 | 0 |
| Milestone | F12M, PL, F12D, MFF | F12D, F12M, MFF, PL | MFF, F12D, PL, F12M | PL, MFF, F12M, F12D |
|---|---|---|---|---|
| Started | 7 | 9 | 8 | 7 |
| Completed | 7 | 9 | 8 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | F12M, PL, F12D, MFF | F12D, F12M, MFF, PL | MFF, F12D, PL, F12M | PL, MFF, F12M, F12D |
|---|---|---|---|---|
| Started | 7 | 9 | 8 | 7 |
| Completed | 7 | 9 | 8 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | F12M, PL, F12D, MFF | F12D, F12M, MFF, PL | MFF, F12D, PL, F12M | PL, MFF, F12M, F12D |
|---|---|---|---|---|
| Started | 7 | 9 | 8 | 7 |
| Completed | 7 | 9 | 8 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
For FEV1 AUC(0-12h) the trapezoidal rule was applied using planned time measurements to calculate the AUC up to and including the last measurement recorded before intake of rescue medication. The AUC was standardized by dividing by the length of time for which measurements of FEV1 were included in the calculation of the AUC thus adjusting for subjects who were unable to complete the measurements during the 12-hour observation period and without inhaling rescue medication. The unit of the AUC was in L, being a weighted average of the acceptable FEV1 measurements recorded over 12 hours post dose
| liters | MFF10 | F12M | F12D | Placebo |
|---|---|---|---|---|
| The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment | 1.77 ± .042 | 1.77 ± .042 | 1.80 ± .042 | 1.71 ± .042 |
All efficacy evaluations were based on spirometry assessments of lung function. FEV1 is the maximum amount of air expired in one second. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the (ATS / ERS) standards.
| liters | MFF10 | F12M | F12D | Placebo |
|---|---|---|---|---|
| 5 minutes | 1.74 (1.70 to 1.79) | 1.77 (1.72 to 1.81) | 1.77 (1.73 to 1.82) | 1.68 (1.63 to 1.72) |
| 30 minutes | 1.79 (1.75 to 1.84) | 1.80 (1.75 to 1.85) | 1.82 (1.77 to 1.87) | 1.69 (1.64 to 1.74) |
| 1 hour (N=32, 31, 29, 31) | 1.81 (1.75 to 1.87) | 1.80 (1.74 to 1.86) | 1.86 (1.79 to 1.92) | 1.72 (1.66 to 1.78) |
| 2 hours | 1.81 (1.74 to 1.87) | 1.79 (1.72 to 1.85) | 1.85 (1.79 to 1.91) | 1.73 (1.67 to 1.79) |
| 4 hours | 1.81 (1.73 to 1.88) | 1.79 (1.71 to 1.87) | 1.84 (1.76 to 1.92) | 1.72 (1.64 to 1.80) |
| 8 hours | 1.76 (1.69 to 1.83) | 1.75 (1.69 to 1.82) | 1.79 (1.72 to 1.86) | 1.70 (1.63 to 1.77) |
| 12 hours | 1.72 (1.67 to 1.78) | 1.71 (1.65 to 1.76) | 1.76 (1.70 to 1.81) | 1.66 (1.61 to 1.72) |
All efficacy evaluations were based on spirometry assessments of lung function. FVC is the volume (liters) of air that can forcibly be blown out after full inspiration. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS / ERS standards.
| liters | MFF10 | F12M | F12D | Placebo |
|---|---|---|---|---|
| 5 minutes | 2.09 (2.04 to 2.14) | 2.09 (2.05 to 2.14) | 2.09 (2.04 to 2.13) | 2.08 (2.03 to 2.13) |
| 30 minutes | 2.12 (2.07 to 2.17) | 2.11 (2.06 to 2.16) | 2.11 (2.06 to 2.16) | 2.08 (2.03 to 2.13) |
| 1 hour (N=32, 31, 29, 31) | 2.14 (2.09 to 2.20) | 2.09 (2.03 to 2.14) | 2.15 (2.09 to 2.21) | 2.10 (2.04 to 2.15) |
| 2 hours | 2.11 (2.05 to 2.17) | 2.08 (2.02 to 2.14) | 2.14 (2.08 to 2.20) | 2.11 (2.05 to 2.17) |
| 4 hours | 2.12 (2.06 to 2.17) | 2.08 (2.02 to 2.14) | 2.12 (2.07 to 2.18) | 2.11 (2.05 to 2.17) |
| 8 hours | 2.09 (2.04 to 2.15) | 2.09 (2.04 to 2.15) | 2.10 (2.04 to 2.15) | 2.09 (2.04 to 2.15) |
| 12 hours | 2.07 (2.01 to 2.13) | 2.05 (1.99 to 2.11) | 2.09 (2.03 to 2.15) | 2.06 (2.00 to 2.12) |
All efficacy evaluations were based on spirometry assessments of lung function. PEF is the greatest airflow rate achieved during forced exhalation with lungs fully inflated. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS/ERS standards
| liters | MFF10 | F12M | F12D | Placebo |
|---|---|---|---|---|
| 5 minutes | 246.65 (238.31 to 254.99) | 248.17 (239.72 to 256.63) | 250.05 (241.48 to 258.62) | 237.85 (229.40 to 246.30) |
| 30 minutes | 255.69 (245.56 to 265.81) | 253.37 (243.14 to 263.59) | 257.81 (247.48 to 268.14) | 243.59 (233.36 to 253.82) |
| 1 hour (N=32, 31, 29, 31) | 261.18 (250.97 to 271.38) | 257.08 (246.79 to 267.38) | 262.95 (252.47 to 273.43) | 248.24 (237.94 to 258.54) |
| 2 hours | 261.45 (250.74 to 272.17) | 259.28 (248.45 to 270.10) | 267.91 (256.98 to 278.84) | 248.88 (238.05 to 259.70) |
| 4 hours | 264.68 (253.09 to 276.26) | 258.92 (247.24 to 270.60) | 265.20 (253.42 to 276.98) | 249.07 (237.39 to 260.76) |
| 8 hours | 257.96 (246.21 to 269.72) | 255.27 (247.41 to 267.12) | 262.61 (250.65 to 274.56) | 248.47 (236.61 to 260.33) |
| 12 hours | 255.48 (243.94 to 267.02) | 250.71 (239.06 to 262.37) | 259.71 (248.05 to 271.37) | 244.13 (232.59 to 255.66) |
Unchanged racemic formoterol in plasma was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for plasma was 1.45 pmol/L. No non-compartmental PK analysis was performed.
| pmol/L | MFF10 | F12M | F12D |
|---|---|---|---|
| Pre-Dose (N count MFF=15,F12M=17,F12D=16) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| 5-10 minutes (N=16, 17, 17) | 13.1 ± 12.2 | 16.3 ± 18.6 | 18.56 ± 9.19 |
| 30 minutes - 2 hours (N=16,17,17) | 27.5 ± 12.2 | 24.7 ± 18.7 | 23.1 ± 11.08 |
| 2 hours - 4 hours (N= 16, 17, 17) | 22.4 ± 15.1 | 17.7 ± 10.5 | 17.4 ± 6.44 |
| 4 hours - 8 hours (N= 16, 17, 17) | 12.3 ± 8.07 | 11.0 ± 5.3 | 11.3 ± 4.42 |
| 8 hours - 12 hours (N= 16, 16, 17) | 7.74 ± 5.68 | 6.66 ± 5.7 | 6.83 ± 4.76 |
Unchanged racemic formoterol in urine was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for urine was 0.0174 nmol/L expressed as free base. The amounts of unchanged formoterol excreted in urine from 0 to 3 hours (Ae0-3) and from 0 to 12 hours post-dose (Ae0-12) were calculated from the formoterol concentrations in urine and the urine volumes using non-compartmental methods.
| nmol | MFF10 | F12M | F12D |
|---|---|---|---|
| Ae (0-3) nmol (N=15,17,17) | 0.31 (0.20 to 0.49) | 0.52 (0.33 to 0.80) | 0.42 (0.27 to 0.65) |
| Ae (0-12) nmol (N=16,17,17) | 1.14 (0.81 to 1.59) | 1.50 (1.08 to 2.08) | 1.33 (0.96 to 1.85) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| F12M | — | 0/31 (0%) | 0/31 (0%) |
| F12D | — | 0/31 (0%) | 0/31 (0%) |
| MFF10 | — | 0/32 (0%) | 0/32 (0%) |
| Placebo | — | 0/31 (0%) | 0/31 (0%) |
| Age, Categorical(Participants) | F12M, PL, F12D, MFF | F12D, F12M, MFF, PL | MFF, F12D, PL, F12M | PL, MFF, F12M, F12D | Total |
|---|---|---|---|---|---|
| <=18 years | 7 | 9 | 9 | 7 | 32 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age Continuous(years) | F12M, PL, F12D, MFF | F12D, F12M, MFF, PL | MFF, F12D, PL, F12M | PL, MFF, F12M, F12D | Total |
|---|---|---|---|---|---|
| Mean | 9.0 ± 1.63 | 9.4 ± 1.51 | 7.9 ± 1.83 | 10.1 ± 1.21 | 9.1 ± 1.72 |
| Sex: Female, Male(Participants) | F12M, PL, F12D, MFF | F12D, F12M, MFF, PL | MFF, F12D, PL, F12M | PL, MFF, F12M, F12D | Total |
|---|---|---|---|---|---|
| Female | 2 | 6 | 5 | 4 | 17 |
| Male | 5 | 3 | 4 | 3 | 15 |
| Ethnicity (NIH/OMB)(Participants) | F12M, PL, F12D, MFF | F12D, F12M, MFF, PL | MFF, F12D, PL, F12M | PL, MFF, F12M, F12D | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 5 | 2 | 11 |
| Not Hispanic or Latino | 5 | 7 | 4 | 5 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | F12M, PL, F12D, MFF | F12D, F12M, MFF, PL | MFF, F12D, PL, F12M | PL, MFF, F12M, F12D | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 1 | 0 | 3 |
| White | 5 | 4 | 3 | 4 | 16 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 3 | 5 | 2 | 12 |
The record gives a start of Aug 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mometasone Furoate · Formoterol